CMPX

Compass TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$4.50

+116.3% vs current

Most likely

Base case

45%

Probability

Target price

$1.90

-8.7% vs current

B-

Bear case

35%

Probability

Target price

$0.80

-61.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

This remains a cautious monitoring setup, not a high-conviction recovery call. Headline buzz is high because the major repricing followed the late-April COMPANION-002 secondary-endpoint debate, and the May 5, 2026 earnings release mostly reinforced existing talking points rather than clearly changing the thesis. Immediate post-print analyst reaction appears limited relative to the earlier clinical shock, while available revision signals skew negative because visible firms cut targets or downgraded after the BTC readout. With low coverage and no new decisive earnings surprise beyond cash runway and pipeline timing, confidence should stay capped.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-07eventFDA interaction and potential BLA path for tovecimigHigh impact

Management said tovecimig received Orphan Drug Designation in April 2026 and that Compass intends to meet with the FDA before a planned BLA submission later in 2026; if regulators accept the crossover-confounded BTC dataset as reviewable, the stock could rerate, but this remains contingent on FDA feedback and is not de-risked by the Q1 print alone [#8-K-2026-05-05].

2026-08-07eventASCO 2026 CTX-8371 updateHigh impact

Compass said CTX-8371 dose-escalation results and initial expansion-cohort data will be presented at ASCO 2026, after deep responses in TNBC, NSCLC and Hodgkin lymphoma prompted expansion cohorts; this is the nearest pipeline datapoint beyond BTC and matters because it tests whether the company has a second credible value driver [#8-K-2026-05-05].

2027-05-09catalystAdditional 2026 pipeline readouts and trial startsHigh impact

Compass guided to initial CTX-10726 clinical data in Q4 2026 and expects to start the Phase 2 CTX-471 NCAM-positive tumor study in 2H 2026; success would broaden the story beyond tovecimig, while slippage would reinforce the current single-asset overhang [#8-K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology